BioCentury
ARTICLE | Company News

DUSA, Sun Pharmaceutical deal

December 24, 2012 8:00 AM UTC

Sun completed its tender offer to acquire DUSA for $8 per share in cash, or about $230 million. Sun said it would complete the acquisition via a short-form merger (see BioCentury, Nov. 12). ...